COMMUNIQUÉS West-GlobeNewswire

Atsena Therapeutics Announces Initiation of Dosing in Second Cohort of Phase I/II Clinical Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
13/03/2024
Subretinal injection of ATSN-201 was well tolerated in all patients in first cohort with no serious adverse events reported Enrollment is ongoing in first clinical trial utilizing AAV.SPR, the company’s novel spreading [...]
Vanqua Bio to Present at the Stifel 2024 CNS Days Conference
13/03/2024
CHICAGO, March 13, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced today that [...]
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
13/03/2024
WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
13/03/2024
Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiat ing Multi-Dosing for patients with solid tumors NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP [...]
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
13/03/2024
Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic- [...]
HOOPP delivers 9.38% return in 2023: success bolstered by strong Canadian portfolio
13/03/2024
TORONTO, March 13, 2024 (GLOBE NEWSWIRE) -- The Healthcare of Ontario Pension Plan (HOOPP) announced today that it delivered a 9.38% return in 2023, bringing its net assets to $112.6 billion, up from $103.7 billion at [...]
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
13/03/2024
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will [...]
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
13/03/2024
– Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 – – Completed dosing for third cohort of Phase 1 clinical trial of [...]
Antheia and Olon Continue Partnership for Biomanufacturing Antheia’s Pipeline of KSMs and APIs for Essential Medicines
13/03/2024
Olon to support Antheia’s continued scale up and commercialization of early products MENLO PARK, Calif. and MILAN, Italy, March 13, 2024 (GLOBE NEWSWIRE) -- Antheia , the pharmaceutical ingredient manufacturer [...]
Appointment of new CEO
13/03/2024
ANNOUNCEMENT NO. 255 (Changed category - Inside information) Appointment of new CEO The Board of Directors of ChemoMetec has decided to appoint the company's current COO Martin Helbo Behrens as new CEO, effective as of [...]
Appointment of new CEO
13/03/2024
ANNOUNCEMENT NO. 254 Appointment of new CEO The Board of Directors of ChemoMetec has decided to appoint the company's current COO Martin Helbo Behrens as new CEO, effective as of today. The decision is based on the [...]
Faron’s Financial Statement Release January 1 to December 31, 2023
13/03/2024
TURKU, Finland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. ("Faron" or "the Company") (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers [...]
Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024
13/03/2024
Press Release Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024 Focusing resources on the clinical development of Nicox’s lead program NCX 470 in glaucoma NCX 470 [...]
Nicox fait le point sur les perspectives de son développement, de son portefeuille de produits et de son financement et tiendra une réunion par webcast le 18 mars 2024
13/03/2024
Communiqué de presse Nicox fait le point sur les perspectives de son développement, de son portefeuille de produits et de son financement et tiendra une réunion par webcast le 18 mars 2024 Ressources concentrées sur le [...]
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
13/03/2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong fourth quarter performance, with net sales 1 of USD 2.5 billion, up 10% in constant currencies (up 11% in USD) Full-year 2023 [...]
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
13/03/2024
$250,000 top award goes to Achyuta Rajaram in the nation’s oldest and most prestigious Science, Technology, Engineering and Math (STEM) competition for high school seniors TARRYTOWN, N.Y. and WASHINGTON, D.C., March 12 [...]
Intelligent Bio Solutions Announces Closing of $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
13/03/2024
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
iSpecimen Reschedules Full Year 2023 Earnings Release and Conference Call
13/03/2024
The Company will now report results after the market closes on March 13, 2024 and reschedules conference call to Thursday, March 14, 2024 at 8:30am Eastern LEXINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- iSpecimen [...]
Scorpius Holdings, Inc. Announces Closing of Public Offering
12/03/2024
DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced [...]

Pages